Innocan Pharma boasts impressive achievements in efficacy tests, commercialization and IP

Ronald Kaufman Independent Analyst

Innocan Pharma Corporation (CSE: INNO, FSE: IP4), a pharmaceutical tech company, has announced significant achievements over the past few weeks in drug delivery platform technologies, efficacy tests, commercialization and intellectual property (IP) development in the cannabis industry.

The company has filed a joint patent application with Ramot at Tel Aviv University with the World Intellectual Property Organization to develop a drug delivery platform that maximizes the activity of loaded cannabinoids. Innocan's innovative platform aims to load cannabinoids on exosomes to expand the IP space for cannabis-based products. Innocan's CEO, Iris Bincovich, noted that the joint application reflects the strength of their collaboration and the potential of their partnership.

Innocan Pharma's portfolio of targeted healing products continues to expand, positioning the company as a leader in the field of cannabis-based therapeutics. The company has reported successful results of an efficacy test for its vaginal derma product that contains cannabinoids, phytoestrogens, hyaluronic acid, and probiotics. The product offers a healthy alternative for women seeking relief from vaginal discomfort and has been proven effective in a 56-day trial conducted with a group of female volunteers.

The pharmaceutical tech company has also launched a CBD veterinary commercialization team dedicated to licensing and commercializing their CBD therapy in the veterinary field. The company plans to engage with prospective clients to explore potential collaborations and commercialization opportunities. The company believes that the veterinary market represents a significant opportunity for growth and expansion.

Moreover, Innocan Pharma has received a Notice of Allowance from the United States Patent and Trademark Office for its patent application related to a combined cannabis and magnesium topical pain-relief technology. The patent covers breakthrough technology designed to relieve pain and itching topically using spray, roll-on, or lotion. The patent approval would aid the company's commercialization efforts.

Innocan is a pharmaceutical tech company that operates under two main segments: Pharmaceuticals and Consumer Wellness. The Pharmaceuticals segment focuses on developing innovative drug delivery platform technologies, comprising cannabinoids science, to treat various conditions to improve patients' quality of life. The Consumer Wellness segment develops and markets a wide portfolio of innovative and high-performance self-care products to promote a healthier lifestyle.

While Innocan has outpaced the CSE and HMMJ (Horizons Marijuana Life Sciences Index) over the past three months, it still seems that there is potentially substantial room for gains given its impressive milestones.

Innocan Pharma's recent achievements in drug delivery platform technologies, efficacy tests, commercialization, and IP development in the CBD and Pharma industry are impressive. The company's dedication to improving patients' quality of life through innovative technologies and consumer wellness products positions Innocan as a leader in the CBD-based therapeutics and care markets. As the company continues to expand its portfolio of targeted healing products and patent application filings, it's exciting to see what other breakthroughs Innocan Pharma will bring to the cannabis industry in the near future.

Author

Ronald Kaufman

Independent Analyst

Ronald Kaufman a writer and blogger active in the fields of foodtech, pharma, cyber, biotech and more. Ronald writes for leading publications about a number of topics.

AUD/USD sits at three-week highs above 0.7000 on hawkish RBA-speak

AUD/USD holds a positive bias for the fourth straight day, trading above 0.7000 in the Asian session on Wednesday and at three-week highs. RBA Deputy Governor Andrew Hauser's hawkish remarks and inflation concerns underpin the pair. However, the upside appears capped as the US Dollar attracts some buyers amid looming US-Iran uncertainty.

USD/JPY remains confined in a familiar range below 158.50

USD/JPY sees some dip-buying in the Asian session on Wednesday, though it remains confined within a multi-week range near 158.50 as the uncertainty over the timing of the next BoJ rate hike keeps Japanese Yen bulls on the defensive. Meanwhile, hawkish Fed expectations, bolstered by inflation risks stemming from volatile oil prices, underpin the US Dollar. However, looming intervention fears could limit JPY losses and cap the currency pair.

Gold appears slightly bid above $4,100

Gold prices manage to reverse three consecutive daily declines, trading just above the $4,100 per troy ounce on Wednesday. The yellow metal’s recovery comes amid a humble advance in the US Dollar, mixed US Treasury yields across the board and a widespread cautious tone from the US-Iran front.

Bitcoin eyes a break above $85,000 as institutional demand returns

Bitcoin edges higher above $83,000, extending its rebound from the 50-day EMA near $80,786. US-listed BTC spot ETFs recorded over $23 million in net inflows on Tuesday, following Monday's $526 million, signaling a return of institutional demand.

What November 3 means for the Fed's rate path and the US Dollar

The USD faces a decisive period ahead of the November 3 midterm elections. While markets anticipate another interest rate increase from the Fed in December, the battle for control of Congress could reshape fiscal policy expectations and, indirectly, the path of US monetary policy in 2027.

The US Dollar fell. Gold didn't rally. That tells you everything

Gold (XAU/USD) is struggling to capitalize on a weaker US Dollar (USD), after repeatedly failing to establish itself above the $4,200 level. The precious metal remains confined to a relatively narrow trading range despite a combination of developments that would normally support higher prices.